Elon Musk said a third person has received an implant from his brain-computer interface company Neuralink, one of many groups working to connect the nervous system to machines. “We’ve got ... three humans with Neuralinks and all are working well,” he said during a wide-ranging interview at a Las Vegas event streamed on his social media platform X.

Neuralink’s three implants are part of its ongoing Prime study, which is evaluating the safety of Neuralink’s brain device in individuals with quadriplegia. In September 2024, the company announced the approval of a second study known as Convoy, which will explore extending its brain device capabilities to control an assistive robotic arm.

A third patient received a brain implant from Neuralink, a neurotechnology company founded by Elon Musk. The billionaire said, "We’ve got ... three humans with Neuralinks and all are working well," during a wide-ranging interview at a Las Vegas event streamed on his social media platform X.

Elon Musk announced that Neuralink has implanted its third patient, marking a milestone. The company is upgrading its brain-computer interface and plans to expand trials with 20-30 more implants this year,

Neuralink Corp., founded by Elon Musk, continues to push the boundaries of brain-computer interface technology. The company recently announced that its brain implant device has been successfully implanted in three human patients, with plans for an ambitious rollout of 20 to 30 more implants by 2025.

Elon Musk's Neuralink brain implant has been approved by Health Canada for clinical trials in Canada. Dr. Andres Lozano, a neurosurgeon at Toronto Western Hospital, discusses the upcoming clinical trials and how the technology could help people with disabilities due to spinal cord injuries or ALS.

During a live event broadcast on the X network, Musk announced that a third patient has received the company’s brain-computer interface implant, according to Ziare. This news comes as part of ongoing developments in Neuralink’s experimental technologies.